BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Kidney cancer (RCC) clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for renal cell carcinoma: 182 (132 sponsors; 17 newly posted in the last 180 days, 9 stopped in the last 180 days; 13 new-entrant sponsors). Momentum score 6, rank 86 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 75, Phase 2 60, Phase 3 20, Phase 4 0, N/A 25.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Merck Sharp & Dohme LLC MRK | 12 | P3 7, P2 4, P1 1 | 0 | 1 |
| Exelixis EXEL | 6 | P3 3, P1 3 | 1 | 2 |
| Bristol-Myers Squibb BMY | 7 | P1 2, NA 1, P2 2, P3 2 | 1 | 1 |
| AstraZeneca AZN | 6 | P2 1, P3 2, P1 2, NA 1 | 0 | 2 |
| Telix Pharmaceuticals (Innovations) Pty Limited TLX | 4 | P3 2, P2 1, P1 1 | 1 | 0 |
| Arcus Biosciences, Inc. RCUS | 3 | P3 1, P1 2 | 0 | 0 |
| EMD Serono Research & Development Institute, Inc. | 2 | P1 1, P3 1 | 0 | 1 |
| Eisai Inc. | 1 | P3 1 | 0 | 0 |
| Xynomic Pharmaceuticals, Inc. | 1 | P3 1 | 0 | 1 |
| Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 4 | P2 2, P1 2 | 0 | 2 |
| Regeneron Pharmaceuticals REGN | 4 | P2 4 | 1 | 0 |
| A2 Biotherapeutics Inc. | 3 | NA 2, P2 1 | 0 | 0 |
| GI Innovation, Inc. | 3 | P2 3 | 0 | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 3 | P1 2, P2 1 | 0 | 1 |
| Elephas | 2 | NA 2 | 0 | 1 |
| Eli Lilly and Company LLY | 2 | P1 2 | 0 | 2 |
| HiFiBiO Therapeutics | 2 | P1 2 | 0 | 2 |
| Ipsen | 2 | NA 2 | 0 | 1 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2 | P2 1, P1 1 | 0 | 0 |
| 23andMe, Inc. | 1 | P2 1 | 0 | 0 |
| 3D Medicines (Sichuan) Co., Ltd. | 1 | P2 1 | 0 | 1 |
| 7 Hills Pharma, LLC | 1 | P2 1 | 0 | 0 |
| AccSalus Biosciences, Inc. | 1 | P1 1 | 0 | 0 |
| Actuate Therapeutics Inc. ACTU | 1 | P2 1 | 0 | 0 |
| Adela, Inc | 1 | NA 1 | 0 | 1 |
Recently stopped trials
- NCT05462873 Novartis Pharmaceuticals - terminated: Business decision and not related to safety concerns A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
- NCT05935748 NiKang Therapeutics, Inc. - terminated: This study was terminated as a result of Sponsor portfolio reprioritization. Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
- NCT02875548 Epizyme, Inc. - terminated: Sponsor decision; no additional participant enrollment was anticipated. A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazem
- NCT06480565 Adicet Therapeutics - terminated: Sponsor decision A Phase 1 Trial of ADI-270 in ccRCC
- NCT05879822 Incyte Corporation - terminated: This was a strategic business decision. There were no safety concerns contributing to this decision. A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
- NCT07181720 Chongqing Precision Biotech Co., Ltd - suspended: Sponsor stopped the study. CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
- NCT05826600 iOmx Therapeutics AG - terminated: Study terminated as part of strategic considerations and not based on safety concerns. A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
- NCT07100925 Ankyra Therapeutics, Inc - withdrawn: Strategic realignment A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
- NCT04458259 Pfizer - terminated: Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P1/P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT05024214 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | Solid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma | recruiting | 170 |
| 2026-12-15 est. | P3 | Exelixis EXEL | NCT05678673 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | Non-Clear Cell Renal Cell Carcinoma | active not recruiting | 317 |
| 2026-12-22 est. | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT05468697 A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LI | Renal Cell Carcinoma | active not recruiting | 60 |
| 2026-12-30 est. | P3 | Xynomic Pharmaceuticals, Inc. | NCT03592472 A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | Renal Cell Carcinoma | recruiting | 413 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P1/P2 | Arsenal Biosciences, Inc. | NCT06245915 AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) | Advanced/Metastatic Clear Cell Renal Cell Carcinoma; Recurrence | active not recruiting | 37 |
| 2026-12-31 est. | P2 | Imbioray (Hangzhou) Biomedicine Co., Ltd. | NCT07087158 A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | recruiting | 30 |
| 2027-02 est. | P1/P2 | Beijing Scitech-Mq Pharmaceuticals Limited | NCT06127238 Study of ST-1898 in Advanced Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | active not recruiting | 90 |
| 2027-02 est. | P1/P2 | GI Innovation, Inc. | NCT07172802 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer (NSCLC); Head and Neck (HNS | recruiting | 102 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-10-28 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT05239728 A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrec | Carcinoma, Renal Cell | active not recruiting | 1800 |
| 2026-10-05 | P2 | Hoffmann-La Roche | NCT05805501 A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinom | Renal Cell Carcinoma | completed | 199 |
| 2026-08-28 | P2/P3 | Hutchmed HCM | NCT05522231 Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | Advanced Renal Cell Carcinoma | completed | 265 |
| 2026-08-10 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04626479 Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | Carcinoma, Renal Cell | completed | 393 |
| 2026-07-23 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04626518 Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | Carcinoma, Renal Cell | completed | 263 |
| 2026-07-01 est. | P1/P2 | Scancell Ltd SCNLD | NCT05329532 Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer | Triple Negative Breast Cancer; Renal Cell Cancer; High Grade Ovarian Serous Adenocarcinoma; Squamous | recruiting | 168 |
| 2026-06-30 est. | P3 | Telix Pharmaceuticals (Innovations) Pty Limited TLX | NCT06750419 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | Clear Cell Renal Cell Carcinoma | recruiting | 82 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "renal cell carcinoma"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.